Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data [Yahoo! Finance]
Cybin Inc. (HELP)
Company Research
Source: Yahoo! Finance
The company has multiple psychedelic drug candidates at various stages, including potential treatments for depression and anxiety disorders. Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data David Smart/Shutterstock.com On March 5, Cybin Inc (NASDAQ:HELP) reported topline results from a Phase 2 study of its drug candidate HLP004, which targets patients with generalized anxiety disorder (GAD). That study enrolled three dozen patients who were already on antidepressant therapy but remained symptomatic. According to the company, HLP004 reduced anxiety symptoms by 10 points on a rating scale. This improvement was above what was already being seen from antidepressant therapy. Moreover, HLP004 was well-tolerated. The benefits of HLP004 were sustained through at least six months, the company said. Helus Pharma's other drug candidate, HLP003, is in Phase 3 study for treating major depressive disorder. The company looks to release data on the HLP003 study in Q4 2026. Cyb
Show less
Read more
Impact Snapshot
Event Time:
HELP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HELP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HELP alerts
High impacting Cybin Inc. news events
Weekly update
A roundup of the hottest topics
HELP
News
- Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer [Yahoo! Finance]Yahoo! Finance
- Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People OfficerGlobeNewswire
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- A Look At Cybin (HELP) Valuation After Positive Phase 2 HLP004 Anxiety Data [Yahoo! Finance]Yahoo! Finance
- Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder [Yahoo! Finance]Yahoo! Finance
HELP
Earnings
- 2/13/26 - Miss
HELP
Sec Filings
- 4/10/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/23/26 - Form D
- HELP's page on the SEC website